ZA200201592B - Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia. - Google Patents
Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia. Download PDFInfo
- Publication number
- ZA200201592B ZA200201592B ZA200201592A ZA200201592A ZA200201592B ZA 200201592 B ZA200201592 B ZA 200201592B ZA 200201592 A ZA200201592 A ZA 200201592A ZA 200201592 A ZA200201592 A ZA 200201592A ZA 200201592 B ZA200201592 B ZA 200201592B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- coo
- conh
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 15
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims description 11
- 229940124530 sulfonamide Drugs 0.000 title 1
- -1 CONHo Chemical group 0.000 claims description 66
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 33
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 30
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 20
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 18
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 18
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 18
- 125000003386 piperidinyl group Chemical group 0.000 claims description 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 12
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 12
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 12
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 12
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 12
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 11
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 11
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims description 11
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 9
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 9
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 9
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 6
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 6
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 5
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 3
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 3
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 3
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 4
- 239000003524 antilipemic agent Substances 0.000 claims 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19941559A DE19941559A1 (de) | 1999-09-01 | 1999-09-01 | Verwendung von Bissulfonamiden zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidömie |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200201592B true ZA200201592B (en) | 2003-01-29 |
Family
ID=7920369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200201592A ZA200201592B (en) | 1999-09-01 | 2002-02-26 | Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia. |
Country Status (23)
Country | Link |
---|---|
US (1) | US6632838B1 (zh) |
EP (1) | EP1237859B1 (zh) |
JP (1) | JP4982021B2 (zh) |
KR (1) | KR20020023429A (zh) |
CN (1) | CN1384742A (zh) |
AT (1) | ATE380789T1 (zh) |
AU (1) | AU775336B2 (zh) |
BR (1) | BR0013723A (zh) |
CA (1) | CA2383783A1 (zh) |
CZ (1) | CZ2002708A3 (zh) |
DE (2) | DE19941559A1 (zh) |
EE (1) | EE200200088A (zh) |
HR (1) | HRP20020178A2 (zh) |
HU (1) | HUP0204282A2 (zh) |
IL (1) | IL148147A0 (zh) |
MX (1) | MXPA02001740A (zh) |
NO (1) | NO20020812L (zh) |
NZ (1) | NZ517485A (zh) |
PL (1) | PL353205A1 (zh) |
RU (1) | RU2002107996A (zh) |
SK (1) | SK2722002A3 (zh) |
WO (1) | WO2001016096A2 (zh) |
ZA (1) | ZA200201592B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100922486B1 (ko) * | 2001-05-11 | 2009-10-20 | 바이오비트럼 에이비(피유비엘) | 비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한신규한 아릴술폰아미드 화합물 |
US7718650B2 (en) * | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
CA2443724C (en) * | 2001-05-11 | 2009-11-03 | Patrizia Caldirola | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
WO2006012025A1 (en) * | 2004-06-25 | 2006-02-02 | Polyone Corporation | Intumescent polyolefin nanocomposites and their use |
JP4925629B2 (ja) * | 2005-09-02 | 2012-05-09 | 住友化学株式会社 | スルホンアミド化合物 |
WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
UY31468A1 (es) * | 2007-11-15 | 2009-07-17 | Derivados bis-(sulfonilamino) en terapia 065 | |
TW200930369A (en) * | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
US20090163586A1 (en) * | 2007-12-20 | 2009-06-25 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 205 |
US20100292279A1 (en) * | 2009-05-14 | 2010-11-18 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1353357A (en) * | 1970-09-14 | 1974-05-15 | Pfizer | Substituted 5-sulphamylbenzoic acids |
NL7310889A (zh) * | 1972-08-12 | 1974-02-14 | ||
DE2459394A1 (de) * | 1974-12-16 | 1976-06-24 | Hoechst Ag | Basisch substituierte benzol-1,3- disulfonamide und verfahren zu ihrer herstellung |
FR2517202B1 (fr) * | 1981-12-02 | 1986-07-04 | Choay Sa | Compositions pharmaceutiques presentant des proprietes normolipemiantes et contenant des composes ayant une structure du type benzenesulfonamides n-substitues |
DE3713757A1 (de) * | 1987-04-24 | 1988-11-10 | Hoechst Ag | Benzolsulfonamidderivate und verfahren zu ihrer herstellung |
DE3905075A1 (de) * | 1989-02-18 | 1990-08-30 | Hoechst Ag | Benzolsulfonamide und verfahren zu ihrer herstellung |
-
1999
- 1999-09-01 DE DE19941559A patent/DE19941559A1/de not_active Withdrawn
-
2000
- 2000-08-17 RU RU2002107996/14A patent/RU2002107996A/ru not_active Application Discontinuation
- 2000-08-17 JP JP2001519666A patent/JP4982021B2/ja not_active Expired - Fee Related
- 2000-08-17 CZ CZ2002708A patent/CZ2002708A3/cs unknown
- 2000-08-17 IL IL14814700A patent/IL148147A0/xx unknown
- 2000-08-17 HU HU0204282A patent/HUP0204282A2/hu unknown
- 2000-08-17 NZ NZ517485A patent/NZ517485A/en unknown
- 2000-08-17 EE EEP200200088A patent/EE200200088A/xx unknown
- 2000-08-17 MX MXPA02001740A patent/MXPA02001740A/es active IP Right Grant
- 2000-08-17 SK SK272-2002A patent/SK2722002A3/sk unknown
- 2000-08-17 WO PCT/EP2000/008026 patent/WO2001016096A2/de active IP Right Grant
- 2000-08-17 CN CN00812133A patent/CN1384742A/zh active Pending
- 2000-08-17 PL PL00353205A patent/PL353205A1/xx not_active Application Discontinuation
- 2000-08-17 DE DE50014850T patent/DE50014850D1/de not_active Expired - Lifetime
- 2000-08-17 AT AT00962330T patent/ATE380789T1/de not_active IP Right Cessation
- 2000-08-17 CA CA002383783A patent/CA2383783A1/en not_active Abandoned
- 2000-08-17 EP EP00962330A patent/EP1237859B1/de not_active Expired - Lifetime
- 2000-08-17 AU AU74099/00A patent/AU775336B2/en not_active Ceased
- 2000-08-17 BR BR0013723-5A patent/BR0013723A/pt not_active IP Right Cessation
- 2000-08-17 KR KR1020027002627A patent/KR20020023429A/ko not_active Application Discontinuation
- 2000-08-31 US US09/653,253 patent/US6632838B1/en not_active Expired - Lifetime
-
2002
- 2002-02-19 NO NO20020812A patent/NO20020812L/no not_active Application Discontinuation
- 2002-02-26 ZA ZA200201592A patent/ZA200201592B/en unknown
- 2002-02-27 HR HR20020178A patent/HRP20020178A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US6632838B1 (en) | 2003-10-14 |
HUP0204282A2 (hu) | 2003-06-28 |
AU7409900A (en) | 2001-03-26 |
CA2383783A1 (en) | 2001-03-08 |
EP1237859B1 (de) | 2007-12-12 |
EE200200088A (et) | 2003-04-15 |
EP1237859A2 (de) | 2002-09-11 |
DE19941559A1 (de) | 2001-03-15 |
WO2001016096A3 (de) | 2002-07-04 |
IL148147A0 (en) | 2002-09-12 |
ATE380789T1 (de) | 2007-12-15 |
CN1384742A (zh) | 2002-12-11 |
DE50014850D1 (de) | 2008-01-24 |
PL353205A1 (en) | 2003-11-03 |
NZ517485A (en) | 2004-01-30 |
JP2003508381A (ja) | 2003-03-04 |
AU775336B2 (en) | 2004-07-29 |
HRP20020178A2 (en) | 2004-02-29 |
CZ2002708A3 (cs) | 2002-05-15 |
WO2001016096A2 (de) | 2001-03-08 |
SK2722002A3 (en) | 2002-07-02 |
NO20020812D0 (no) | 2002-02-19 |
NO20020812L (no) | 2002-04-30 |
RU2002107996A (ru) | 2003-11-20 |
MXPA02001740A (es) | 2002-08-06 |
BR0013723A (pt) | 2002-05-07 |
KR20020023429A (ko) | 2002-03-28 |
JP4982021B2 (ja) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20020033778A (ko) | 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도 | |
CY1119001T1 (el) | Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας | |
ZA200201592B (en) | Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia. | |
NO20051303L (no) | Nye benzoimidazolderivater nyttige som antiproliferative midler | |
JP2005519024A5 (zh) | ||
PT582789E (pt) | 7-(substituidas)-8-(substituidas)-9-(glicil substituido) amido-6-desmetil-6-desoxitetraciclinas | |
AU2001250783A1 (en) | Benzamides and related inhibitors of factor xa | |
EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
RU2003128992A (ru) | Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток | |
RU94045149A (ru) | Средство ингибирования легочных гипертонических заболеваний | |
JP7071287B2 (ja) | 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 | |
AR054770A1 (es) | Oxoindoles como inhibidores de quinasas, un metodo para su elaboracion, composiciones farmaceuticas que los contienen y su preparacion, un juego de elementos que los utiliza y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por proteinas quinasas mek1 o mek2. | |
RU2003130635A (ru) | Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболевания, подобных аллергическим нарушениям | |
RU2015110256A (ru) | Бензофуразановые антимилоидные соединения и способы | |
JP2006512321A5 (zh) | ||
KR880005927A (ko) | 카복실산 아미드의 용도 | |
ZA200106439B (en) | Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity. | |
SE9904412D0 (sv) | Comminuted form | |
KR930700441A (ko) | 1-피페리디닐 알카노일아릴 술폰아미드 유도체 | |
ZA200201593B (en) | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments. | |
CN115103850A (zh) | 2-甲氧基雌二醇衍生物及其医学用途 | |
GB1530931A (en) | N-(1-(4-phenyl-4-oxobutyl)-4-piperidyl)-2-thiophene carboxamide | |
RU2002106739A (ru) | Новые ингибитора интергрина αvβ3 | |
AR024762A1 (es) | Monoester [3-({1-[2-(4-fluorofenil)etil]piperidin-4-il}hidroximetil)-2-metoxifenilico]del acido sulfurico | |
ES380930A1 (es) | Un procedimiento de preparacion de nuevas 2-hidroxi-5-aminobenzamidas. |